Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Acacia rigidula* (now often reclassified as *Senegalia rigidula*) is a perennial shrub native to southern Texas and central Mexico. In the context of the dietary supplement industry, extracts of the plant have been marketed for weight loss, energy enhancement, and athletic performance, purportedly due to the presence of various phenethylamine alkaloids. However, the substance gained significant notoriety when the FDA and independent researchers discovered that many supplements labeled as containing *Acacia rigidula* actually contained the synthetic stimulant beta-methylphenethylamine (BMPEA), which is not naturally occurring in the plant. The plant itself contains a complex mixture of amines, including phenethylamine (PEA), tyramine, and tryptamine, which are thought to act as sympathomimetic agents. Due to the presence of undeclared synthetic stimulants and lack of safety data for the botanical extract itself, the FDA has issued multiple warning letters to manufacturers, effectively removing it from the legitimate supplement market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acacia rigidula.